Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR: Palbociclib + Endocrine Therapy in HR+/HER2- Recurrent Breast Cancer
NCT03820830Phase 3Active, not recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Aug 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Invasive Disease Free Survival. Started Aug 2019; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03820830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820830.